Paramount Skydance Corp. is a worldwide media entertainment company. Paramount Global merged into Skydance Media on August 7, 2025. The publicly held Class B shares trade under the ticker symbol PSKY, comprise 30% of the equity of Paramount Skydance, and have no voting rights. An investor consortium led by the Ellison family and private-equity firm RedBird Capital hold a 70% equity interest and 100% of the voting rights in the company. Paramount produces and distributes television and cable programming over its networks, including the flagship CBS broadcast network; a stable of basic cable channels, including MTV Networks, VH1, Nickelodeon, Country Music Television, Comedy Central, and BET; a network of owned and affiliated local CBS broadcast television stations; and two digital streaming video platforms, its flagship Paramount+ service and advertising-supported Pluto TV. Paramount also produces and distributes theatrical films through its Paramount Pictures studio and owns a minority 12.5% share in the CW network. The company's businesses and trademarks also include the Showtime cable network and CBS Television Distribution.

Stock indices saw minor gains on Wednesday and, once again, the fireworks were in individual names. There also was an explosion in the metals, crypto currencies, and the U.S. Dollar Index (USD). All the action was driven by headlines -- and for a day in August when we are supposed to be in the summer doldrums, things were quite newsy. The Treasury made a surprise announcement that it would at least double its long-term bond buyback operations, which sent the USD tumbling almost 0.9%. Bitcoin popped 8%, Ethereum soared 18%, and Solana spiked 13% on the greenback dive, a heavy dose of short covering, and hopes for market-structure legislation. Bitcoin poked its head above its bear-market trendline off the peaks since October 2025, with both Ethereum and Solana surging above their bear line. Gold (GLD) surged almost 4% and ran right into its 200-day average, while Silver (SLV) bolted 4.5% and remains 7% under its 200-day. GLD has broken its bear-market trendline off the peak since January 2026 while SLV stopped right at its bearish trendline.

Biogen is a biotech company that develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases. The company is the market leader in MS drugs and launched the first approved treatments for spinal muscular atrophy and AD. The company also sells products that treat plaque psoriasis, non-Hodgkin's lymphoma, lymphocytic leukemia, and rheumatoid arthritis. Current research continues on MS and has expanded to include neuroimmunology, ophthalmology, lupus, and other neuromuscular and movement disorders. Founded in 1978, the company is located in Cambridge, Massachusetts; employs 7,500 people; and is a component of the S&P 500.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).